Moderna
MRNA
962 hedge funds and large institutions have $30.2B invested in Moderna in 2023 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 308 increasing their positions, 380 reducing their positions, and 124 closing their positions.
0.48% more ownership
Funds ownership: 64.65% → 65.13% (+0.48%)
10% less call options, than puts
Call options by funds: $1.32B | Put options by funds: $1.46B
5% less funds holding
Funds holding: 1,015 → 962 (-53)
14% less capital inflows, than outflows
Capital inflows: $1.44B | Capital outflows: $1.67B
17% less funds holding in top 10
Funds holding in top 10: 18 → 15 (-3)
19% less repeat investments, than reductions
Existing positions increased: 308 | Existing positions reduced: 380
47% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 124
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$116M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$112M |
| 3 |
Two Sigma Investments
New York
|
+$83.6M |
| 4 |
JP Morgan Chase
New York
|
+$70.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$66.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$124M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$101M |
| 3 |
Jane Street
New York
|
-$99.3M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$97.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$90.5M |
MRNA Hedge Fund Activity: Q2 2023 in Review
962 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q2 2023, worth a combined $30.2B — down 21% from $38.4B a quarter earlier.
Sellers outnumbered buyers: 124 funds closed out of MRNA and 66 opened new positions — a net loss of 58 holders — while 380 trimmed existing stakes and 308 added.
The largest buyer was Morgan Stanley, adding an estimated $116M. The largest seller was BlackRock, cutting an estimated $124M.
- 962 institutional investors held Moderna (MRNA) as of Q2 2023, down from 1,015 in Q1 2023.
- Funds reported $30.2B of Moderna stock for Q2 2023, down 21% quarter-over-quarter.
- 66 funds opened new Moderna positions in Q2 2023 and 124 closed out, a net change of -58 holders.
- The largest Moderna buyer in Q2 2023 was Morgan Stanley, an estimated $116M added.
- The largest Moderna seller in Q2 2023 was BlackRock, an estimated $124M sold.
Based on aggregated 13F filings for Q2 2023.